What meds close a PDA?

Medications Used to Close a Patent Ductus Arteriosus in Premature Infants

When a premature infant is born, one of the challenges doctors may face is a patent ductus arteriosus (PDA)—a condition where a blood vessel that should close shortly after birth remains open. This small but persistent connection between two major blood vessels near the heart can lead to complications like heart failure or respiratory distress if left untreated.

Thankfully, medical science offers a non-surgical approach to help close the PDA in preterm babies. The primary treatment involves the use of medications known as prostaglandin synthesis inhibitors, most commonly indomethacin or aspirin. These drugs work by blocking the production of prostaglandins, substances that keep the ductus arteriosus open during fetal life. By reducing their levels, the ductus is encouraged to close naturally.

Indomethacin, in particular, has been widely used in neonatal intensive care units. A typical dose is around 0.1 mg/kg of body weight, administered orally every eight hours under careful medical supervision. The treatment is most effective when started within the first few days of life, especially in infants born significantly before term.

While the procedure is generally safe, close monitoring is essential to watch for potential side effects, such as reduced blood flow to the kidneys or the gastrointestinal tract. In some cases, if medication fails or isn’t suitable, doctors may consider a minimally invasive procedure or surgery.

With timely and appropriate treatment, many premature infants respond well to pharmacologic PDA closure, paving the way for improved outcomes and shorter hospital stays. As neonatal care continues to advance, these medications remain a cornerstone in managing this common preterm condition.